WebCullinan Oncology's is goal is to create new standards of care for patients with cancer Cullinan Oncology has built a diversified pipeline by identifying high-impact … Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug … At Cullinan Oncology, our research is anchored in a deep understanding of … Zipalertinib (CLN-081/TAS6417) A Phase 1/2a, Open-label, multicenter, first-in … A Robust Pipeline Powered by Modality-Agnostic Targeted Oncology Taking a … www.cullinanoncology.com CAMBRIDGE, Mass., Jan. 12, 2024 (GLOBE NEWSWIRE) -- Cullinan … Being a small biotechnology company, Cullinan Oncology’s teams are nimble, … WebCullinan Oncology Nov 2024 - Present 6 months. Cambridge, Massachusetts, United States ... Associate Director, Program …
Cullinan Oncology LinkedIn
WebMay 12, 2024 · Cullinan Oncology will co-develop CLN-081/TAS6417 and will retain the option to co-commercialize CLN-081/TAS6417 in the United States together with Taiho Pharmaceutical through its U.S. subsidiary ... WebCullinan Oncology 1 year 9 months Senior Director, Senior Corporate Counsel Feb 2024 - Present3 months Boston, Massachusetts, United … chinese symbol for unity
Sebastian Tomlin - Associate Director, Distribution …
WebApr 12, 2024 · Awarded 1.0 contact hour (s) of nursing continuing professional development for RNs and APNs; 0.50 contact hours are in the area of pharmacology. Contact This Provider For Pharmacists Medscape designates this continuing education activity for 1.0 contact hour (s) (0.100 CEUs) (Universal Activity Number: JA0007105-0000-23-081-H01 … WebCullinan Oncology Dec 2024 - Present5 months Charles River Laboratories 4 years 9 months Associate Director, Logistics Jan 2024 - … grandview heights swim and dive